BioCardia Announces FDA Approval of Its IND for NK1R+ Mesenchymal Stem Cells for the Treatment of Patients Recovering from Acute Respiratory Distress due to COVID-19
Phase I/II trial initiation expected in 3Q 2022 SUNNYVALE, Calif., April 12, 2022 (GLOBE NEWSWIRE)…